

Pharnext Presents a Business Update Webcast on May 20th, 2020

PARIS, France, 6:00 pm, May 14, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today confirmed the organization of a webcast to update on its current activities on **May 20th, 2020 at 6:00 pm (CET)**.

During this webcast, **David Horn Solomon, Chief Executive Officer**, will provide a business update and overview of Pharnext.

Attendees can participate by **weblink**: https://channel.royalcast.com/webcast/pharnext/20200520_1/ or connect by phone using the following coordinates:

Confirmation Code: Pharnext

Dials-in:

- USA: +1 212 999 6659
- France: +33 (0) 1 7099 4740
- UK: +44 (0) 20 3003 2666

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer's disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. Pharnext identifies and develops synergic combinations of drugs called PLEODRUG™. The Company was founded by renowned scientists and entrepreneurs, including Professor Daniel Cohen, pioneer in modern genomics, and is supported by a world-class scientific team. More information at www.pharnext.com.

Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).

Contacts

Pharnext

David Solomon
Chief Executive Officer
contact@pharnext.com
+33 (0)1 41 09 22 30

Media Relations (Europe)

Ulysse Communication
Bruno Arabian
+33 (0)6 87 88 47 26
barabian@ulyse-communication.com
Pierre-Louis Germain
+33 (0)6 64 79 97 51
plgermain@ulyse-communication.com
+33 (0)1 81 70 96 30

Financial Communication (France)

Actifin
Stéphane Ruiz
sruiz@actifin.fr
+33 (0)1 56 88 11 15

Investors Relations (U.S.)

Stern Investor Relations, Inc.
Jane Urheim
jane.urheim@sternir.com
+1 212 362 1200